The CLEAR study compared clinical outcomes and health resource usage in patients with severe asthma who continued, switched, or stopped their biologic treatment.
Your search for oral corticosteroids returned 23 results
In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.
The updated labeling is based on results from a safety management cohort from the ZUMA-1 study.
The approval was based on data from the phase 3 JADE clinical trial program, which included the JADE MONO-1, JADE MONO-2, and JADE COMPARE trials.
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Zolgensma is an adeno-associated virus vector-based gene therapy.
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 VOYAGE trial.
Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.